NCT01705587View on ClinicalTrials.gov

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
OsteoporosisAtypical Femoral Fracture
Interventions
DRUG

teriparatide

20 microgram once-daily subcutaneous injection

Trial Locations (1)

15213

University of Pittsburgh, Osteoporosis Prevention & Treatment Center, Pittsburgh

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

lead

Susan L. Greenspan

OTHER

NCT01705587 - Fracture (FX) Improvement With Teriparatide: FiX-IT Study | Biotech Hunter | Biotech Hunter